Citations

Clear

912 citation(s) found for "Yu, Caroline".

603 SUPRAME: a phase 3 trial evaluating IMA203 PRAME-directed TCR T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma
Moser, Justin, Amaria, Rodabe N, Warner, Allison Betof, Chmielowski, Bartosz, Fecher, Leslie A, Chandrasekaran, Sanjay, Chen, Ruqin, Cowey, Charles L, Daniels, Gregory A, Daud, Adil, Dimitrova, Maya, Dudek, Arkadiusz Z, Haugh, Alexandra, Hernandez-Aya, Leonel, Hu-Lieskovan, Siwen, Hurwitz, Michael E, Isaacs, James M, Karapetyan, Lilit, Lee, Sylvia, Mammen, Joshua MV, Mckean, Meredith, Mitchell, Tara C, Moschos, Stergios J, Naqash, Abdul Rafeh, Olson, Daniel J, Olszanski, Anthony J, Patel, Sapna P, Poklepovic, Andrew S, Robert, Caroline, Schadendorf, Dirk, Seedor, Rino S, Seetharam, Mahesh, Smithy, James W, Solomon, Benjamin M, Taylor, Matthew H, Terhune, Julia H, Viray, Hollis A, Whitman, Eric D, Wu, Richard, Xing, Yan, Krishna, Delfi, Mayer-Mokler, Andrea, Pankov, Dmitry, Britten, Cedrik M, Luke, Jason J, Moser, Justin, Amaria, Rodabe N, Warner, Allison Betof, Chmielowski, Bartosz, Fecher, Leslie A, Chandrasekaran, Sanjay, Chen, Ruqin, Cowey, Charles L, Daniels, Gregory A, Daud, Adil, Dimitrova, Maya, Dudek, Arkadiusz Z, Haugh, Alexandra, Hernandez-Aya, Leonel, Hu-Lieskovan, Siwen, Hurwitz, Michael E, Isaacs, James M, Karapetyan, Lilit, Lee, Sylvia, Mammen, Joshua MV, Mckean, Meredith, Mitchell, Tara C, Moschos, Stergios J, Naqash, Abdul Rafeh, Olson, Daniel J, Olszanski, Anthony J, Patel, Sapna P, Poklepovic, Andrew S, Robert, Caroline , Schadendorf, Dirk, Seedor, Rino S, Seetharam, Mahesh, Smithy, James W, Solomon, Benjamin M, Taylor, Matthew H, Terhune, Julia H, Viray, Hollis A, Whitman, Eric D, Wu, Richard, Xing, Yan, Krishna, Delfi, Mayer-Mokler, Andrea, Pankov, Dmitry, Britten, Cedrik M, Luke, Jason J

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A687-A687

10.1136/jitc-2025-sitc2025.0603 Get It

Development and pilot of a tool evaluating community-engaged group processes and community-centered impact for institutional level advisory boards
Allen, Michele , Graff, Yasamin, Carlin, Caroline , Apolinário-Wilcoxon, Antonia, Baukol, Paulette, Boman, Kristin , Brewer, LaPrincess, Dwivedi, Roli , Eder, Milton , Gust, Susan, Hang, Mikow, Novillo, Walter, Ortega, Luis, Pergament, Shannon , Pulley, Chris, Shirley, Rebecca, Ly-Xiong, Sida, Baukol, Paulette, Brewer, LaPrincess, Gust, Susan, Shirley, Rebecca

Mayo Clinic

Journal of Clinical and Translational Science | October 28, 2025 | Volume: 9 | Issue: 1 | Pages: No page available

10.1017/cts.2025.10177 | PMID 41496783 Get It

Abstract Introduction: While evaluation approaches for community-academic research groups are established, few tools exist for academic institutional advisory groups across multi-core centers and research, education, and clinical care missions. Institutional advisory group evaluation should consider group processes and their impact on community-centered outcomes. This study describes the community-engaged development of a mixed-method evaluation approach to address this gap and presents pilot outcomes across an NIH-funded center. Methods: We utilized a Community of Practice model to co-develop a survey with 14 community and academic representatives of four advisory groups. The final survey included five categories of group process and four categories of outcomes. Storytelling sessions with community partners explored areas where the survey identified discrepancies in perspectives between community and academic team members, as well as areas with lower scores. Results: Nine community and 14 academic (staff and faculty) partners completed the survey. Respondents positively assessed group process outcomes (shared values, leadership, community-centeredness, and decision-making), and slightly less positive assessments of institutional outcomes. Storytelling sessions confirmed the overall satisfaction of community partners but highlighted actionable concerns within power-sharing, decision-making, funding equity, and trust-building. Conclusions: The results of this equity-centered evaluation suggest the utility and importance of participatory, mixed-methods approaches to evaluating community-academic institutional advisory groups.
Topobexin Targets a Unique Druggable Pocket of Topoisomerase II for Beta Isoform- Selective Control of DNA Damage During Anthracycline Chemotherapy
Lencova, Olga, Piskackova, Hana Bavlovic, Keresteš, Veronika , Applová, Lenka , Arrouye, Lise C. M., Alvey, Julia R , Paluncic, Jasmina , Witter, Taylor L. , Schellenberg, Matthew J. , Kubes, Jan , Karabanovich, Galina , Cong, Anh , Melnikova, Iuliia , Kollárová-Brázdová, Petra , Jirkovská, Anna , Kuneš, Jiřı́ , Štěrbová‐Kovaříková, Petra , Austin, Caroline , Štěrba, Martin , Šimůnek, Tomáš , Roh, Jaroslav

Mayo Clinic

Structural Dynamics | October 27, 2025 | Volume: 12 | Issue: 5_Supplement | Pages: A359-A359

10.1063/4.0001148 Get It

Anthracyclines are potent chemotherapeutic agents, yet their clinical use is hampered by their cardiotoxicity. Anthracyclines achieve potent anti- cancer effects primarily via TOP2A, but at the same time they induce a dose limiting cardiotoxicity through TOP2B. The use of a catalytic TOP2 inhibitors such as dexrazoxane (ICRF 187) significantly reduces the incidence of anthracycline-induced cardiotoxicity. However, dexrazoxane targets the highly conserved TOP2 dimer interface that is identical between TOP2A and TOP2B, fostering persisting concerns that its inhibition of TOP2A isoenzyme may interfere with anthracycline anticancer effects and augment anthracycline-induced myelosuppression. Thus, isoform- selective TOP2 inhibitors that can control the DNA damage caused by TOP2A vs TOP2B are a significant unmet clinical need. We have developed a new class of highly potent and TOP2B-selective catalytic inhibitors through rational design by building upon the general pharmacophore present in isolates from Calophyllum Brasiliense. Using X-ray crystallography, we demonstrate that our newly developed compounds occupy a previously unidentified druggable binding-site in the TOP2 ATPase domain and function as a physical barrier to block the conformational change triggered by ATP hydrolysis. We have named the class of inhibitors that target this site “obex”, the Latin word for obstacle. The obex binding site contains residues that differ between the TOP2A and TOP2B isoenzymes, based on which we rationally designed, prepared, and systematically evaluated a targeted panel of obex inhibitors. We have identified the lead molecule, namely, topobexin, as the first- in-class TOP2B-specific obex inhibitor that can prevent anthracycline-induced DNA damage. This first TOP2 isoform-specific inhibition underscores the broader potential to improve drug specificity and minimize adverse effects in various medical treatments.
Evaluating Multidisciplinary Post-AKI Care Delivery in Primary Care: Videographic Analysis of the ACT Program
Determan, Meina Louise, Ledet, Caroline B., Kattah, Andrea G. , Frazee, Erin N. , May, Heather P. , Determan, Meina L. , Ledet, Caroline B., Griffin, Joan M. , Kashani, Kianoush , McCoy, Rozalina G. , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | October 23, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.20258j349wp2 Get It

Application of Machine Learning for Predicting Progression‐Free and Overall Survival in Patients With Renal Cell Carcinoma
Grant, Caroline W. , Li, Jerry , Lin, Swan , Nickens, Dana J., Ouellet, Danièle , Shahin, Mohamed H.

Mayo Clinic

Clinical and Translational Science | October 23, 2025 | Volume: 18 | Issue: 10 | Pages: No page available

10.1111/cts.70348 | PMID 41127951 Get It

ABSTRACT Patient outcomes in advanced renal cell carcinoma (RCC) remain poor, with five‐year survival rates ranging from ~10% to 30%. Early projections of therapeutic outcomes could optimize precision medicine and accelerate drug development. While machine learning (ML) models integrating tumor growth inhibition (TGI) metrics have improved survival predictions over traditional models, their application in RCC remains unexplored. Herein, we used TGI metrics and baseline data to evaluate parametric (PM) and semi‐parametric (SPM) survival models alongside ML approaches for predicting progression‐free (PFS) and overall survival (OS) in 1839 RCC patients from four trials (evaluating sunitinib, axitinib, sorafenib, interferon‐alpha, and avelumab + axitinib). Data were split into training (70%) and testing (30%), and feature selection was used to determine parsimonious and robust models. Bootstrap resampling ( n = 100) was employed for models' validation, and performance was assessed using C‐index and Integrated Brier Score. In brief, training data results demonstrated that tree‐based ML models (random survival forest (RSF) and XGBoost) outperformed PM and SPM models in predicting PFS (C‐index: 0.783–0.785 vs. 0.725–0.738 for PM and SPM; p < 0.05) and OS (C‐index: 0.77–0.867 vs. 0.750–0.758 for PM and SPM; p < 0.05), with RSF achieving better prediction of PFS and OS using only 3–5 covariates, compared to 9–35 with other tested methods. Tree‐based methods were also superior in the testing data. SHapley Additive exPlanations revealed nonlinear relationships among top predictors, including TGI metrics, underscoring the ability of tree‐based methods to capture complex prognostic interactions. Further validation is required to confirm models' generalizability to additional therapies and patients with differing tumor severity.
The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea
Mifsrud, Caroline S., Rushlow, David , Mifsud, Caroline S, Kolla, Bhanu Prakash , Mansukhani, Meghna P.

Mayo Clinic

Expert Opinion on Pharmacotherapy | October 20, 2025 | Volume: 26 | Issue: 14-15 | Pages: 1529-1538

10.1080/14656566.2025.2574848 | PMID 41114602 Get It

Disparity in Timely Breast Cancer Treatment: Concordance with Commission on Cancer Quality Measures and the Influence of Socioeconomic Factors in the National Cancer Database
Nataliansyah, M. Muska , Xing, Yun , Boughey, Judy Caroline, Lizarraga, Ingrid M. , Xing, Yun, Boughey, Judy C. , Snyder, Rebecca A. , Mobley, Erin Michele

Mayo Clinic

Journal of the American College of Surgeons | October 16, 2025 | Volume: 242 | Issue: 1 | Pages: 79-89

10.1097/xcs.0000000000001649 | PMID 41100569 Get It

BACKGROUND: Significant disparities persist in timely, guideline-concordant breast cancer treatment across the US, impacting cancer outcomes. The influence of both patient-level and facility-level socioeconomic status (SES) on adherence to Commission on Cancer quality measures remains incompletely understood. STUDY DESIGN: We conducted a retrospective cohort study using the National Cancer Database to assess associations between patient and facility SES and concordance with timeliness of 3 Commission on Cancer breast cancer quality measures: surgery, multiagent chemotherapy, and radiotherapy, among patients diagnosed from 2018 to 2022. Multivariable logistic regression models were used to evaluate predictors of concordant care, including a composite measure of facility-level social risk. RESULTS: The analytic cohorts included 471,425 patients for surgery, 82,734 for chemotherapy, and 311,523 for radiotherapy. Black race, uninsured status, and lower educational attainment were each independently associated with lower odds of receiving guideline-concordant care across all measures. Patients treated at low-SES facilities had higher odds of receiving timely surgery (adjusted odds ratio [OR] 1.27, 95% CI 1.24 to 1.31) but lower odds of receiving timely chemotherapy (OR 0.85, 95% CI 0.79 to 0.91) and radiotherapy (OR 0.95, 95% CI 0.92 to 0.97) compared with those at other institutions. Facility type, fragmented care, and comorbidities also contributed to variation in concordance. CONCLUSIONS: Significant disparities in guideline-concordant breast cancer care persist by race, insurance, education, and facility-level social risk, highlighting intervention opportunities to improve outcomes for these already vulnerable populations. These findings highlight the importance of policy and institutional strategies that address both patient- and facility-level barriers to ensure equitable access to high-quality multidisciplinary treatment.
Brachial-Ankle Pulse Wave Velocity Is Associated with Kidney Function Decline in Adults Undergoing Cardiovascular Disease Screening
Ledet, Caroline B. , Arslan, Meliksah , Dyke, Kylie Van , Malik, A. Rauoof , Kullo, Iftikhar J. , Van Dyke, Kylie, Kullo, Iftikhar J , Dyke, Kylie Van

Mayo Clinic

Kidney360 | October 10, 2025 | Volume: 7 | Issue: 2 | Pages: 291-301

10.34067/kid.0000000973 | PMID 41071605 Get It

Key Points We studied the link between brachial-ankle pulse wave velocity (baPWV) and CKD risk in adults undergoing cardiovascular disease screening. A higher baseline baPWV was predictive of an increased annualized rate of creatinine-based eGFR (eGFR Cr ) decline. Compared with normal baPWV, higher baseline baPWV was associated with increased risk of developing CKD and lower CKD-free survival time. Background CKD affects 35 million adults in the United States and is associated with high morbidity and mortality. We investigated whether brachial-ankle pulse wave velocity (baPWV), a noninvasive measure of arterial stiffness, was associated with kidney function decline in adults undergoing cardiovascular disease (CVD) screening. Methods In 1862 patients referred for an exercise electrocardiogram test between 2007 and 2009, baPWV was measured using an Omron Colin oscillometric device. Creatinine-based GFR was estimated (eGFR Cr ) for participants with available baseline and follow-up creatinine values using the CKD Epidemiology Collaboration formula. We performed multivariable linear regression analyses to assess whether baseline baPWV was associated with annualized change in eGFR Cr , after adjustment for age, sex, body mass index, baseline eGFR Cr , and traditional CVD risk factors, including mean arterial pressure, diabetes and hypertension diagnoses, nephroprotective medication use, smoking status, and total cholesterol. To determine risk of developing CKD and CKD-free survival time by arterial stiffness subgroups, we performed covariable-adjusted Cox proportional hazards modeling and a Kaplan-Meier survival analysis, respectively. Results After exclusion of participants with missing covariable data and adjustment for covariables, one SD increase in baPWV was associated with a 0.18 ml/min per 1.73 m 2 BSA greater yearly decrease in eGFR Cr ( P = 0.023) over a median follow-up time of 13.2 years. Participants with higher baseline baPWV had increased risk of CKD (hazard ratio [95% confidence interval], P value; elevated baPWV: 2.4 [1.1 to 5.4], P = 0.037; borderline-elevated baPWV: 1.8 [1.1 to 3.1], P = 0.028) and had a shorter CKD-free survival time (median CKD-free survival time [years]; normal baPWV: 16.2; borderline-elevated baPWV: 16.0; elevated baPWV: 15.6 [ P < 0.001]). Conclusions Elevated baPWV, a noninvasive measure of arterial stiffness that can be obtained in the office setting, was associated with decline in kidney function, risk of CKD development, and CKD-free survival in individuals undergoing CVD screening.
Discovery and Validation of Molecular Biomarkers for Differentiation of Nondysplastic Barrett’s Esophagus from High-grade Dysplasia and Esophageal Adenocarcinoma
Matchett, Caroline L. , Taylor, William R. , Berger, Calise K. , Anderson, Caryn E., Passe, Melissa, Lansing, Ramona, Wang, Panwen , Chalmers, Collin E., Foote, Patrick H. , Eckel‐Passow, Jeanette E. , Codipilly, Don C. , Leggett, Cadman L. , Ramirez, Francisco C. , Wolfsen, Herbert C. , Eluri, Swathi , Konda, Vani J. , Iyer, Prasad G. , Slettedahl, Seth W , Taylor, William R , Berger, Calise K , Anderson, Caryn E , Passe, Melissa A , Lansing, Ramona M , Wang, Panwen , Chalmers, Collin E , Foote, Patrick H , Eckel-Passow, Jeanette E , Sun, Zhifu , Mahoney, Douglas W , Codipilly, Don Chamil , Leggett, Cadman L , Ramirez, Francisco C , Kahn, Allon , Wolfsen, Herbert C , Eluri, Swathi , Konda, Vani , Trindade, Arvind J , Iyer, P G , Kisiel, John B , Slettedahl, Seth W. , Sun, Zhifu , Mahoney, Douglas W. , Kahn, Allon , Trindade, Arvind J. , Kisiel, John B.

Mayo Clinic

Cancer Prevention Research | October 8, 2025 | Volume: 19 | Issue: 1 | Pages: 49-60

10.1158/1940-6207.capr-25-0215 | PMID 41059926 Get It

Abstract Aberrant DNA methylation and copy-number alterations (CNA) drive Barrett’s esophagus progression to esophageal adenocarcinoma; however, their combined utility for early detection is unclear. We aimed to identify and validate methylated DNA markers (MDM) and CNAs to distinguish esophageal adenocarcinoma/high-grade dysplasia (HGD) from nondysplastic Barrett’s esophagus (NDBE). In this multiphase, multicenter study, we discovered and validated MDMs and quantified CNAs utilizing whole-genome methylation sequencing of esophageal brushings. DNA biomarkers identified from discovery were further validated in independent patients with paired esophageal brushing and swallowed capsule sponge samples. MDMs were filtered against a reduced representation bisulfite sequencing dataset obtained from independent tissue samples to advance only concordant candidates. CNA burden was quantified using ichorCNA-derived aneuploidy scores (AS). Two hundred MDMs discovered in HGD (N = 18) and esophageal adenocarcinoma (N = 18) versus NDBE brushing samples (N = 18) were tested in independent samples (N = 146). A 52-MDM panel achieved a cross-validated AUC of 0.88 [95% confidence interval (CI), 0.82–0.95]; the addition of AS improved discrimination of HGD/esophageal adenocarcinoma from NDBE to 0.91 (95% CI, 0.86–0.97) AUC. At 80% specificity, the combined model detected 93% of esophageal adenocarcinoma and 88% of HGD cases. In paired capsule sponge samples, a 58-MDM panel achieved a cross-validated AUC of 0.77 (95% CI, 0.66–0.88); a combined 58-MDM and AS model achieved AUC 0.80 (95% CI, 0.7–0.9). MDMs and AS discerned HGD/esophageal adenocarcinoma from normal esophagus/NDBE in endoscopic brushing and capsule sponge samples. This approach may improve Barrett’s esophagus surveillance. Prevention Relevance: This study demonstrates that combining epigenetic and genomic biomarkers across minimally invasive sampling methods can accurately distinguish HGD/esophageal adenocarcinoma from nondysplastic Barrett’s esophagus, offering promising, less invasive strategies to improve BE surveillance and enable endoscopic therapy for esophageal adenocarcinoma prevention and treatment.
Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study
Peters, Anthea , Nowakowski, Grzegorz S. , Dabas, Rosy , Amoloja, Theresa , Xue, Zhenyi, Koch, Caroline, Waltl, Eva E., Fleury, Isabelle

Mayo Clinic

The Oncologist | October 4, 2025 | Volume: 30 | Issue: 11 | Pages: No page available

10.1093/oncolo/oyaf330 | PMID 41052305 Get It

Abstract Background In the current Canadian treatment landscape for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), eligibility for autologous stem cell transplantation (ASCT) guides the choice of salvage treatment. CD19 chimeric antigen receptor T-cell (CAR-T) therapies have improved outcomes in patients with chemorefractory DLBCL, but access is limited to eligible patients. This subanalysis of the RE-MIND2 observational retrospective cohort study investigated treatment patterns for R/R DLBCL in Canada. Patients and methods Data from patients enrolled in RE-MIND2 treated between 2010 and 2020 at 2 Canadian centers were retrospectively collected from health records. Descriptive statistics were used to analyze baseline characteristics, treatment initiated, and duration of treatment by line of therapy. Results One hundred and nine patients were included; 74.2% of patients were eligible for ASCT as 2L therapy, and 45.4% received transplants. ASCT eligibility for third- (3L) and fourth-line (4L) therapy declined to 17.1% and 5.9%, respectively. Patients received a wide variety of treatments in 3 and 4L. CAR-T therapy became available in 3 and 4L by the end of 2019. Median durations of treatment were &lt;2.6 months in all lines of therapy; median time to next treatment ranged from 3.4 months in 4L to 5.3 months in 2L. Conclusion Results of our study support that ASCT-ineligible patients have a poor prognosis with conventional salvage chemotherapy. Before the availability of novel immunotherapies, no apparent standard of care was observed for Canadian patients with R/R DLBCL who were ineligible for or did not receive ASCT, especially after 2L treatment.